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Abstract
Purpose Liposome and immunoliposome formulations of
two vinca alkaloids, vincristine and vinblastine, were pre-
pared using intraliposomal triethylammonium sucroseocta-
sulfate and examined for their ability to stabilize the drug
for targeted drug delivery in vivo.
Methods The pharmacokinetics of both the encapsulated
drug (vincristine or vinblastine) and liposomal carrier were
examined in Sprague Dawley rats, and the in vivo drug
release rates determined. Anti-HER2 immunoliposomal
vincristine was prepared from a human anti-HER2/neu
scFv and studied for targeted cytotoxic activity in cell
culture, and antitumor eYcacy in vivo.
Results Nanoliposome formulations of vincristine and
vinblastine demonstrated similar pharmacokinetic proWles
for the liposomal carrier, but increased clearance for
liposome encapsulated vinblastine (t1/2 = 9.7 h) relative to
vincristine (t1/2 = 18.5 h). Immunoliposome formulations of
vincristine targeted to HER2 using an anti-HER2 scFv
antibody fragment displayed a marked enhancement in
cytotoxicity when compared to non-targeted liposomal
vincristine control; 63- or 253-fold for BT474 and SKBR3
breast cancer cells, respectively. Target-speciWc activity
was also demonstrated in HER2-overexpressing human
tumor xenografts, where the HER2-targeted formulation
was signiWcantly more eYcacious than either free vincris-
tine or non-targeted liposomal vincristine.
Conclusions These results demonstrate that active
targeting of solid tumors with liposomal formulations of
vincristine is possible when the resulting immunoliposomes
are suYciently stabilized.
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Abbreviations
Chol Cholesterol
3H-CHE Tritiated cholesterylhexadecylether
CLs Conventional liposomes
ILs Immunoliposomes
i.v. Intravenous
DSPC 1,2-Distearoyl-sn-glycero-3-phosphocholine
Ls-VCR Liposomal vincristine
PEG-DSPE N-(Polyethyleneglycol)distearoylphosphati-
dylethanolamine
PL Phospholipid
SSL Sterically stabilized liposomes
TEA Triethylammonium
TEA8SOS Triethylammonium sucroseoctasulfate
VCR Vincristine
Introduction
Liposome formulations of vincristine have been in clini-
cal development for over a decade [5, 14, 46, 48]. Unlike
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anthracyclines, vinca alkaloids are notoriously more diYcult
to formulate stably in liposomes [10, 44, 48, 51]. Simple
pH- or ammonium sulfate gradients are suYcient to load
and stabilize doxorubicin in liposomes [1, 7, 15, 30], help-
ing to give rise to long circulating and highly active formu-
lations that include pegylated liposomal doxorubicin
(Doxil®, Alza/Johnson&Johnson; Palo Alto, CA). Schedule-
dependent drugs such as vincristine [17,  18] would be
expected to beneWt to an even greater extent from a stable
liposome formulation, with controlled release of the drug
from the liposomal carrier, thus resulting in an extended
duration of exposure of the target cancer tissue to the active
drug [2, 12].
In addition, although liposomal vincristine has been
most extensively studied in leukemias and lymphomas
[31, 32, 43, 44, 46], vincristine, as well as vinblastine, have
also shown activity in the treatment of certain solid tumors,
including neuroblastomas [38, 39] and melanoma [24, 25].
Accumulation of nanoparticle drug carriers, such as lipo-
somes, in solid tumors is generally governed by a relatively
selective, but slow extravasation from a “leaky” tumor
microvasculature, as a part of what is commonly referred to
as the enhanced permeability and retention (EPR) eVect
[9, 28]. To fully take advantage of the EPR phenomenon in
treating solid tumors, the liposomal formulation must be
engineered to retain its active contents for the time needed
to eVectuate extravasation, or approximately 24–48 h
[9, 13, 21], and thus allow for release of the active drug
primarily in the near vicinity of the tumor cells.
Finally, newer generations of liposomal delivery
technologies include active targeting moieties such as anti-
bodies to direct the liposomal drugs speciWcally to receptor-
overexpressing tumor cells [36, 42]. Because the targeting
ligand is not directly conjugated to the drug itself, but
instead indirectly to the carrier, stable encapsulation is an
absolute requirement to ensure that the drug arrives intact at
the target site and reduces exposure to non-target tissues
that will arise if the drug becomes bioavailable prematurely
while in the circulation [10, 36, 42].
A variety of strategies has been employed to improve
the stability of liposomal vincristine formulations. The
modiWcation of the lipid composition, and substitution of
sphingomyelin for phosphatidylcholine in the formulation,
substantially improved the stability of encapsulation for
cholesterol-containing formulations [48]. The introduction
of fully saturated dihydrosphingomyelin into the formula-
tion has further improved its stability [19]. The use of high
drug-to-lipid ratio formulations to increase intraliposomal
concentrations of vincristine, and thus reduce its solubility,
has also been shown to improve stability [20]. Finally, the
use of dextran sulfate to complex vincristine has been used
to limit its diVusion from a liposomal carrier, albeit at the
expense of decreased antitumor activity [52].
Here, we describe the preparation of novel liposomal
vincristine and vinblastine formulations stabilized intralip-
osomally with the sulfated non-polymeric polyol sucrose
octasulfate. These preparations were highly stable in vivo
despite the absence of sphingomyelin in the formulation,
and even at relatively low vincristine to phospholipid
ratios. Immunotargeted versions were prepared through
conjugation of a human anti-HER2 scFv to the surface of
the carrier, and shown to result in target-speciWc cytotoxic-
ity in breast cancer cells in culture and improved antitumor
eYcacy in human breast tumor xenografts in vivo. This
proof-of-concept study suggests that immunotargeting of
liposomal vincristine to solid tumors is feasible when the
nanocarriers are suYciently stabilized to limit drug leakage
in the circulation.
Materials and methods
Materials
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] (PEG-DSPE), and 1,2-distearoyl-
sn-Glycero-3-Phosphoethanolamine-N-[Maleimide(Polyethyl-
ene Glycol)2000] (Ammonium Salt) were purchased from
Avanti Polar Lipids (Alabaster, AL). Cholesterol was obtained
from Calbiochem (La Jolla, CA). Sucrose octasulfate (sodium
salt) was purchased from Toronto Research Chemicals,
Inc. (North York, ON, Canada). Sepharose CL-4B and
Sephadex G-75 size exclusion resins, Dowex 50W-8X-200
cation exchange resin, triethylamine, 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)
were all obtained from Sigma-Aldrich (St Louis, MO).
[3H]-Cholesteryl hexadecyl ether was purchased from
Perkin Elmer (Boston, MA). Vincristine sulfate was pur-
chased from Handetech Development Co. (Houston, TX),
and vinblastine sulfate solution USP (American Pharma-
ceutical Partners, Los Angeles, CA) was purchased from
the pharmacy.)
Methods
Liposomal drug preparation
The lipid membranes of vincristine (VCR) and vinblastine
(VBL)-loaded liposomes were composed of DSPC,
cholesterol, and PEG-DSPE at a molar ratio of 3:2:0.015.
The lipids were dissolved in chloroform:methanol (9:1,
vol:vol), and dried by rotary evaporation and subsequently
for 12 h under vacuum (<100 Torr). Triethylammmonium
sucrose octasulfate (TEA8SOS, sulfate group concentrationCancer Chemother Pharmacol (2009) 64:741–751 743
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0.65 M) was prepared from the sodium salt of sucrose octa-
sulfate using ion exchange chromatography as described
previously [11]. The lipids were redissolved in ethanol at
60°C, and mixed with nine volumes of the aqueous
TEA8SOS solution while maintaining the same tempera-
ture. The resulting mixture was extruded 10 times through
polycarbonate membranes (Whatman, Clifton, NJ) having
pore sizes of 0.05, 0.8, or 0.1 m. Unencapsulated
TEA8SOS was removed on a low pressure hand poured
Sepharose CL-4B size exclusion column (400 mm £
25 mm i.d.), eluted with HEPES-buVered dextrose (5 mM
HEPES, 5% dextrose, pH 6.5). Vincristine or vinblastine
was added at the indicated ratio of drug to lipid (100–550 g
drug salt/mol phospholipid), loading was initiated by
adjusting the pH to 6.5 (unless otherwise indicated), and
incubating for 30 min at 60°C, after which, the liposome
suspension was transferred to an ice bath. The liposomal
preparation was puriWed from unencapsulated drug by
Sephadex G-75 gel Wltration chromatography, eluting with
HEPES-buVered saline (pH 6.5). The drug and phospho-
lipid in the puriWed preparation were diluted to fall within
the linear range or each analytical method (1–50 g/ml
VCR and 5–40 M phospholipid) and quantitated spectro-
photometrically at 298 nm following dissolution in methanol
and using a standard phosphate assay [3], respectively.
Liposome size was determined by photon correlation spec-
troscopy using a Coulter N4 Plus particle size analyzer
(Beckman Coulter; Fullerton, CA) and reported as the
volume-weighted average diameter. The liposome preparations
were sterilized by the passage through a 0.2 m syringe
Wlter, and stored at 4°C until use.
Preparation of anti-HER2 immunoliposomal vincristine
HER2-targeted immunoliposomal vincristine was prepared
by co-incubation of vincristine liposomes with the highly
internalizable anti-HER2 scFv F5 [35, 40] conjugated at the
terminal cysteine to an amphiphilic anchor maleimido-
PEG-DSPE essentiallly as described in detail previously
[33, 34]. BrieXy, F5 having free C-terminal cysteine group
was incubated in an aqueous buVer with the solution of
maleimido-PEG-DSPE at the cysteine/maleimide molar
ratio of 4:1, the excess maleimide groups were capped by
reaction with cysteine, and the conjugation product (that
forms micelles) was puriWed from any unreacted protein
and excess quencher using gel chromatography. The conju-
gate was incubated at 60°C with drug-loaded liposomes at a
ratio of 15 g conjugated protein/mol PL, and quenched
on ice for 15 min. Unincorporated F5-PEG-DSPE conju-
gate (if any) was removed using Sepharose CL-4B gel
Wltration chromatography eluted with HEPES-buVered
saline (pH 6.5). This process has been shown previously to
yield approximately 90% incorporation of the F5 targeting
moiety into the liposomal formulation and never resulted in
a loss of greater than 5% of the liposome-encapsulated
VCR or VBL.
Cell culture
Cytotoxicity experiments were performed using the HER-2
overexpressing human mammary carcinoma cell lines
SKBR-3 and BT474-M2 (BT474 cells from American
Type Culture Collection (Rockville, MD). The BT474-M2
subline was established through in vivo propagation of the
original BT474 (ATCC; Manassas, VA) cell line. BrieXy,
BT474 cells were implanted subcutaneously in NCR nu/nu
female mice in the absence of matrigel. Mice that had rap-
idly growing tumors were sacriWced and sublines estab-
lished from cells originating from these tumors. Cells from
various sublines were reimplanted into groups of 10 NCR
nu/nu female mice, and those lines that resulted in greater
than 70% tumor take, and uniform tumor growth rates were
used in future in vivo studies. The M2 subline was the most
eVective of the cell lines evaluated, and was used in all sub-
sequent studies.
SKBR-3 cells were grown in McCoy’s 5-A medium sup-
plemented with 10% fetal bovine serum, 0.1 mg/ml strepto-
mycin sulfate, and 100 U/ml Penicillin G. BT474-M2 cells
were grown in RPMI 1640 medium supplemented with
10% fetal bovine serum, 0.1 mg/ml streptomycin sulfate,
and 100 U/ml Penicillin G. Cells were exposed to medium
containing the indicated drug formulation for 4 h. After
exchange with fresh medium, the cells were allowed to
incubate at 37°C for 2–3 days. Cell viability was deter-
mined by incubation with MTT (0.5 mg/ml) for 2 h, fol-
lowed by solubilization of the formazan product in acidic
isopropanol, and subsequent quantiWcation by absorbance
at 540 nm using a microtiter plate reader. IC50 values were
calculated using linear regression (Microsoft Excel)
between the two drug concentrations bracketing the 50%
viability value.
Pharmacokinetic and in vivo drug retention studies
In vivo stability and circulation of the liposomal drug
formulation were studied in female Sprague-Dawley rats
(190–210 g) with indwelling central venous catheters.
The rats were given a single bolus injection (0.5–0.9 ml)
of  3H-CHE-labeled Ls-VCR or Ls-VBL at a dose of
5 mg/kg. Blood samples (0.25 ml) were drawn at various
times post injection using a heparin-treated syringe and
the blood volume was replenished using phosphate
buVered physiological saline. The blood samples were
diluted with 0.3 ml of ice-cold PBS containing 0.04%
EDTA, weighed, and the blood cells were separated by
centrifugation for 5 min at 6,000 RPM. The supernatant744 Cancer Chemother Pharmacol (2009) 64:741–751
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was collected and assayed for drug by HPLC, and for the
liposome  3H-lipid label by scintillation radioactivity
counting of 30 l of the plasma solution. Radioactivity
standards were made from the 3H-labeled liposome sam-
ple having a known phospholipid concentration and an
equal amount of diluted rat plasma was added to account
for matrix eVects. No dilution was required for the
plasma  3H-labeled liposome concentration to Wt within
the linear range of 0.2–20 nmol phospholipid. The
recovery of 3H-labeled liposomal PL from plasma (vs.
PBS) is 99.4% with a detection limit of 0.025 nmol
phospholipid. Drug analysis was performed by addition
of 50 l of plasma solution to 450 l of methanol. The
samples were then vortexed, cooled to ¡80°C for a min-
imum of 2 h. The liquid samples were transferred
directly to a centrifuge where they equilibrated to near
room temperature while spinning at 13,000 RPM for
10 min. The supernatant was transferred to an auto sam-
pler vial and kept at 4°C until analysis. Plasma drug
recovery was determined by extraction of liposomal
drugs from spiked plasma as described above. Analysis
was conducted on a Dionex HPLC system using a C18
reverse phase silica column (Supelco C-18 column,
250 mm £ 4 mm i.d., particle size of 5 m) preceded by
a Supelco C18 guard column. An injection volume of
50 l was used and the analytes were eluted isocratically
at a Xow rate of 1.0 ml/min with a mobile phase consist-
ing of 0.21 M aqueous triethylammonium acetate pH 5.5
and acetonitrile (63:37). VCR and VBL are typically
eluted in 10.5 min and 15.0 min, respectively, and each
was detected by absorbance at 298 nm using a diode
array detector. No dilution was required for the plasma
VCR/VBL concentration to Wt within the linear range of
0.1–10 g/ml. The linearity of all VCR and VBL star-
dard curves used here was >0.997. The recovery for
VCR and VBL from spiked plasma controls was 100.4
and 102.0%, respectively, and the limit of detection was
0.2 g/ml for each. Agreement between replicate stan-
dard preparations was within 5% and the % relative
standard deviation of 5 consecutive injections was <2%.
Pharmacokinetic parameters including the tissue half-
lives of the drug (t1/2), clearance (CL), the mean resi-
dence time in the tumor (MRT), and the area under the
concentration versus time curve (AUC1) were all deter-
mined by non-compartmental pharmacokinetics data
analysis using PK Solutions 2.0 software (Summit
Research Services; Montrose, CO). Drug release rates
from the liposome were characterized by their half-life
of release times (T1/2), and were calculated using the
exponential constant (), from a single exponential Wt to
the plot of drug/phospholipid ratio versus post injection
time [N(t)=N0e¡ t]. N(t) is the drug-to-PL ratio at time
t and N(0) is the same ratio at time 0. The T1/2 =0 . 6 9 3 / .
Antitumor eYcacy
BT474-M2 cells were propagated in vitro in RPMI-1640
medium with 10% fetal calf serum, 0.1 mg/mL streptomy-
cin sulfate, and 100 U/ml Penicillin G. NCR nu/nu female
mice (5–6 week old; Charles River, Boston, MA) were
subcutaneously implanted (at the base of tail) with 60-day
sustained-release 0.72-mg 17-estradiol pellets (Innovative
Research of America, Inc., Sarasota, FL), and in 2 days
were inoculated subcutaneously with 0.1 ml suspension
containing 2 £ 107 BT474-M2 cells in cell growth medium
containing no additional supplements. The tumor progres-
sion was monitored by palpation and caliper measurements
of the tumors along the largest (length) and the smallest
(width) axis twice a week. The tumor sizes were deter-
mined twice weekly from the caliper measurements using
the formula: tumor volume = [(length) £ (width)2]/2.
At day 20, post tumor cell inoculation, when the tumors
reached about 210 mm3 in size (range 144–274 mm3), the
mice were randomized into 4 groups of 9 animals/group,
and treated by i.v. injection with saline, 1.0 mg/kg of free
VCR, 1.0 mg/kg Ls-VCR, or 1.0 mg/kg anti-HER2-ILs-
VCR. Each treatment group was administered every 7 days
for a total of 3 treatments. General health of the animals
was observed by monitoring alertness, grooming, feeding,
excreta, skin, fur, mucous membrane conditions, ambula-
tion, breathing, posture, and body weight. Statistical signiW-
cance of the therapeutic eVects for diVerent treatment
groups was evaluated using a one-way ANOVA with post
hoc Holm-Sidak test (SigmaStat 3.1) of the tumor sizes at
the end of the study.
Results
Evaluation of liposomal drug capacity under diVerent 
loading conditions
Here we form stable nanoliposomal formulations of vin-
cristine and vinblastine (Fig. 1) using a loading strategy
similar to that described by us previously for CPT-11 and
the histone deacetylase inhibitor, LAQ824 [8, 11]. The drug
is stabilized intraliposomally through complexation of the
titratable (cationic) amine groups of VCR or VBL, and a
highly charged, non-polymer multivalent anion of sucrose
octasulfate (anionic; Fig. 1c), in the liposome interior. The
loading of Ls-VCR using this technology is highly eYcient
for liposomes over a wide range of drug payload (Fig. 2a).
The liposomal drug capacity is indicated by the ratio of
encapsulated drug to liposomal phospholipid (D/L, g/mol).
Between the range of 150–550 g/mol the average loading
eYciency was 100.8 § 5.13% and the resulting drug to
liposomal phospholipid ratio correlated well to the inputCancer Chemother Pharmacol (2009) 64:741–751 745
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Fig. 1 Structure of vincristine 
(a), vinblastine (b), and sucrose 
octasulfate (c). TEA the cation of 
triethylammonium
Fig. 2 The eYciency of VCR 
and VBL loading into 
liposomes. The liposomal drug 
capacity (g drug/mol 
phospholipid) as a function of 
the initial drug/lipid ratio is 
shown as resulting drug/lipid 
ratio (open square) and 
eYciency (Wlled circle) for VCR 
(a), or as resulting drug/lipid 
ratio (open diamond) and 
eYciency (Wlled diamond) for 
VBL (b). Liposomal loading of 
VCR (Wlled circle) is also shown 
as a function of extraliposomal 
solution pH (c)746 Cancer Chemother Pharmacol (2009) 64:741–751
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ratio (R2 = 0.9968). Ls-VBL similarly exhibited eYcient of
drug loading at 150 g VBL/mol PL (measured eYciency
was 102.1 § 8.1%).
The eVect of extraliposomal solution pH on the loading
eYciency of VCR was also studied. The pH imparts mini-
mal inXuence on loading between pH 4.5–7.5, but below
pH 4.5 the loading was dramatically reduced which may be
explained by the decrease in the amount of membrane-
permeant neutral (non-protonated) form of the drug due to
the shift in the drug acid-base equilibrium at these low pH
values. In all subsequent studies, loading was performed at
pH 6.5.
In vivo pharmacokinetics and drug retention
The blood circulation characteristics of two liposomal
vinca alkaloids, Ls-VCR (Fig. 3a) and Ls-VBL (Fig. 3b),
were studied in rats. Ls-VBL demonstrates the advantage of
liposomal encapsulation with regard to circulation by
exhibiting an AUC of 1,076 g h/ml which is 2 orders of
magnitude greater than that typically observed for unencap-
sulated VBL [47]. The Ls-VBL formulation was highly sta-
ble in circulation as indicated by the encapsulated drug/
liposomal phospholipid ratio over time where 73.1% of the
VBL remains within the liposome after 48 h in circulation,
and the drug release T1/2 was calculated to be 41.3 h
(Fig. 3c). With this liposomal VBL formulation, drug dis-
position is controlled by the slow release rate of VBL from
liposomes in vivo, and thus the drug’s apparent PK
parameters are similar to the liposomal PK parameters.
Evaluation of Ls-VCR (101.6 nm and 104 g VCR/mol
PL formulation) shows even greater formulation stability
(T1/2 = 104 h), and reduced systemic clearance (t1/2 = 18.5 h),
compared to the similar composition of Ls-VBL. The blood
half-life of the various Ls-VCR formulations ranged from
12.3 to 31.2 h (Table 1). In the group of the three 76.8 nm
liposomes and the two 101–102 nm liposomes, the formu-
lations with the lowest drug to lipid ratio (95.1 g/mol)
exhibited the longest circulation half-life and mean resi-
dence time. This is consistent with lower drug-to-lipid
ratios resulting in higher lipid doses being administered,
and circulation lifetimes being in part determined by the
dose of liposomal carrier. In addition, relatively small
liposomes (76.8 nm) retain VCR well, and although not
statistically signiWcant, show a trend towards the longest
circulation lifetimes of all formulations tested.
In vitro cytotoxicity
As shown previously [35], anti-HER2-immunoliposomes
were prepared using anti-HER2 scFv (F5)-PEG-DSPE con-
jugates to speciWcally and eVectively internalize into
HER2-overexpressing cancer cells. Anti-HER2 ILs-VCR
also exhibited dramatically improved cytotoxicity in two
diVerent HER2-overexpressing breast cancer cell lines
(BT474-M2 and SKBR3; Fig. 4). The IC50 for anti-HER2-
ILs-VCR is 253-fold lower (p =6 . 8 e ¡8)in SKBR-3 cells
and 63-fold lower (p = 0.016) in BT474-M2 cells, com-
pared to Ls-VCR. The membrane permeable free VCR
exhibits IC50 values of 111 § 24.4 and 67.3 § 10.9 nM for
SKBR-3 and BT474-M2 cells, respectively, which was in
both greater than (p =9 . 7 e ¡5 for SKBR-3 and p = 0.021 for
BT474-M2) the respective values anti-HER2-ILs-VCR
Fig. 3 In vivo pharmacokinetic evaluation of the liposomal drug
formulation stability and circulation as indicated by % injected dose of
the liposomal phospholipid (open square) and VCR (Wlled square)
components of the Ls-VCR formulation (101.6 nm, 104.5 g VCR/mol
phospholipid) (a) and liposomal phospholipid (open diamond) and
VBL (Wlled diamond) of the Ls-VBL formulation (99.5 nm, 152.4 g
VBL/mol phospholipid) (b). Stability as indicated by retention of
the drug within the liposome is shown for Ls-VCR (open square)
and Ls-VBL (open diamond) as % original drug/lipid ratio (c)Cancer Chemother Pharmacol (2009) 64:741–751 747
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(14.8 § 1.44 and 29.3 § 3.06 nM), although in the case of
SKBR3 cells the diVerence was more prominent. These
data suggest that prolonged intracellular exposure to the
drug from the intracellular reservoir improves the activity.
Similar to untreated cells, empty liposomes containing no
drug have no aVect on cell viability at phospholipid concen-
trations equal to the highest used here (unpublished data).
VCR formulation anti-tumor eYcacy against BT474-M2 
xenografts in mice
Evaluation of the in vivo anti-tumor eYcacy of various
VCR formulations was studied in mice with HER2-over-
expressing BT474-M2 xenografts (Fig. 5). In this study,
we compared saline control, free vincristine, nontargeted
Ls-VCR, and anti-HER2-ILs-VCR dosed once weekly
for 3 weeks. Growth curves for the average tumor size
from each treatment group: saline control, free VCR,
Ls-VCR, and anti-HER2-ILs-VCR are displayed in Fig. 5a,
with all treatments having a greater therapeutic eVect
than the saline control. Ls-VCR was similar to, but only
slightly more eYcacious than free VCR. Anti-HER2-ILs-
VCR was the most active of all the tested formulations
with Wve of nine mice showing complete tumor regres-
sion, and signiWcant improvements in eYcacy. One-way
ANOVA with post hoc Holm-Sidak analysis indicates the
therapeutic eVect of anti-HER2-ILs-VCR was signiW-
cantly greater than Ls-VCR (p = 0.025) The non-targeted
Ls-VCR group had one complete regression, and the
saline and free VCR controls had none. The treatment-
related toxicity was well within limits of tolerance as
none of the treatments caused greater than 10% weight
loss (Fig. 5b) or any observable signs of adverse reaction.
In fact, following the last (third) treatment the mice in all
treatment groups gained weight. There was the weight
loss in the saline control the group presumably resulting
from the increasing tumor burden.
Discussion
Vinca alkaloids such as vincristine, vinblastine, and vinorel-
bine are widely used cytotoxic drugs that elicit their eVects
through disruption of microtubules, resulting in metaphase
arrest in dividing cells [41]. Due to their mechanism of
action,  vinca alkaloids are schedule dependent drugs and
thus their activity is aVected by the duration of exposure to
the drug [17, 18]. As such, vinca alkaloids would beneWt
from a controlled release dosage form that would eVectively
prolong the duration of exposure over extended periods of
time. Liposomal nanocarriers represent one such dosage
form that has been extensively studied for its ability to
prolong the pharmacokinetics and subsequent exposure of
various drugs, including vinca alkaloids [2, 9, 12].
However, liposome formulations of vinca alkaloids are
considerably more diYcult to stabilize in vivo when com-
pared to the more widely studied anthracyclines. Possibly,
due to the high propensity of doxorubicin molecules for
self-association, doxorubicin forms highly stable precipi-
tates inside liposomes following loading using simple pH
or ammonium sulfate-gradients [22], and demonstrates
release rates on the order of 100 h in vivo [44]. Using simi-
lar lipid compositions and gradient-loading strategies
allowed achieving the T½ of vincristine leakage from the
liposome equal to 17 h [48]. The rapid release from the
nanoparticle carrier is unfavorable for the drug’s ability to
beneWt from the EPR eVect in treating solid tumors.
Although extravasation eYciency varies depending on
tumor location [16] and the various physicochemical prop-
erties of the liposomal carrier, including size and surface
charge, the maximum accumulation of long-circulating lip-
osomes in tumors has been reported as generally occurring
at about 24–48 h post administration [9, 13, 21]. In humans,
the circulation lifetimes can even be substantially longer than
observed in animal models [27, 49]. Thus, if a substantial
proportion of the encapsulated drug is released prior to the
Table 1 Blood pharmacokinetic analysis of various Ls-VCR and Ls-VBL formulations in rats
a Area under the time-concentration curve
b Blood clearance
c Volume of distribution
d Mean residence time § standard deviation
Drug Size (nm) D/L (g/mol) t1/2 (h) AUC1a (g h/ml) CLb (ml/h) Vdc (ml) MRTd (h)
Ls-VCR 76.8 § 27.2 95.1 31.2 § 6.0 2,903 § 710 1.8 § 0.4 78.1 § 4.2 45.1 § 8.7
76.8 § 27.2 192 18.8 § 1.0 1,923 § 111 2.6 § 0.1 70.5 § 0.1 27.1 § 1.5
76.8 § 27.2 375 20.0 § 1.1 1,834 § 122 2.7 § 0.2 78.5 § 0.8 28.9 § 1.6
101.6 § 25.3 104 18.5 § 5.9 2,275 § 401 2.2 § 0.4 87.6 § 8.0 40.2 § 10.7
101.2 § 25.3 449 16.2 § 2.7 1,624 § 289 3.1 § 0.6 72.2 § 0.7 23.4 § 3.9
125.6 § 32.0 469 12.3 § 1.7 1,093 § 237 4.7 § 1.0 82.2 § 10.2 17.7 § 1.7
Ls-VBL 99.5 § 10.2 152 9.7 § 0.1 1,076 § 68.1 4.7 § 0.3 65.5 § 4.8 14.1 § 0.1748 Cancer Chemother Pharmacol (2009) 64:741–751
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liposomes reaching the tumor; the drug is deprived of an
advantage of the depot eVect whereby the drug is released
locally in close proximity to the tumor cells.
The requirement for stable encapsulation is even more
important for ligand-targeted formulations, where speciWc
delivery to receptor-overexpressing tumor cells is not pos-
sible if the drug is released prematurely before reaching its
site of action [36, 42]. The fact that the ligand is not cova-
lently conjugated to the active therapeutic agent can be a
considerable advantage over other drug immunoconjugates
or immunotoxins that require complicated linker strategies,
and where species-dependent diVerences in linker hydroly-
sis rates complicate the development of these agents [50].
Controlling the rates of drug release through the nanocar-
rier’s physicochemical properties and drug encapsulation
technology [12], obviates the need for hydrolysis of the
chemical linkers. However, perhaps due in part to the rela-
tive instability of vincristine liposome formulations, immu-
notargeted formulations of vincristine have been primarily
studied in readily vascularly accessible hematological can-
cers [43, 44].
A variety of approaches has been advanced to improve
in vivo formulation stability, with varying degrees of suc-
cess depending on the speciWc vinca alkaloid being deliv-
ered. Bally, Mayer, and coworkers successfully substituted
sphingomyelin for phosphatidylcholine in cholesterol-con-
taining liposomal vincristine formulations to limit the diVu-
sion of the drug across the membrane, nearly doubling the
half-life of vincristine release from 17.1 to 33.3 h [48].
These liposomes, termed “Sphingosomes”, are currently
being developed by Hana Biosciences (South San Fran-
cisco, CA) for the treatment of non-Hodgkin’s lymphoma
and acute lymphoblastic leukemia, and have been studied in
both Phase I and II clinical trials [4, 14, 46]. A modiWcation
of this approach uses fully hydrogenated sphingomyelin to
further stabilize the formulation against in vivo drug leak-
age, resulting in an increase in circulation lifetime of the
sphingosomal vincristine in mice to 13.2 h compared to
9.4 h for the control egg sphingomyelin/cholesterol formu-
lation at the injected lipid dose of 150 mol PL/kg [19].
High drug-to-lipid ratios can also enhance the formation
of intraliposomal drug precipitate, and thus reduce the
intraliposome pool of the dissolved, membrane-permeable
form of the drug available for transmembrane diVusion,
which, along with the permeability constant, determines the
drug release rate from the liposomes once in the circulation
[12,  20]. The combination of sphingomyelin/cholesterol
formulations together with high drug-to-lipid ratios perhaps
exceeding the drug solubility product within the liposome
can Wnally give rise to liposomal vincristine with impres-
sive stability (T1/2 for release of 65 h) [20], however, at the
expense of being limited to high drug-to-lipid ratios result-
ing in corresponding reductions in the lipid dose being
administered for a given dose of drug. This may lead to
potentially undesirable consequences for the liposome
blood clearance, as conventional (non-PEGylated) lipo-
some formulations display dose-dependent pharmacokinet-
ics and thus lower lipid doses result in more rapid clearance
via the mononuclear phagocyte system [2, 9, 12]. Although
PEGylated liposomes display pharmacokinetics that are
less dependent on the administered lipid dose, the further
reduction of administered lipid doses of a liposomal carrier
necessitated by a combination of a high potency drug with
a high drug-to-phospholipid ratio may cause increased
clearance of even PEGylated liposomal drugs [12, 23].
While the above-discussed release modiWcation methods
[20] did result in slower release rates for vincristine, the
results for vinorelbine (T1/2 = 11.0 h) or vinblastine (T1/2 =
14.7 h), have not been as successful [45, 51]. This correlates
Fig. 4 In vitro cytotoxic eVect of free VCR (open circle), Ls-VCR
(open square), and anti-HER2-ILs-VCR (open triangle) on HER2
over-expressing breast cancer cell lines SKBR-3 (a) and BT474-M2
(b). The cellular sensitivity to the VCR formulations is shown as a plot
of % viability (compared to untreated cells) as a function of
increasing drug concentration. IC50 values (g/ml) for SKBR-3
cells are: Ls-VCR, 3.04; free VCR, 0.0862; Anti-HER2-ILs-VCR,
0.012; and BT474-M2 cells are: Ls-VCR, 1.53; free VCR, 0.0557;
Anti-HER2-ILs-VCR, 0.0243Cancer Chemother Pharmacol (2009) 64:741–751 749
123
with the increased hydrophobicity of vinblastine and vinorel-
bine, relative to vincristine [26], and thus their greater mem-
brane permeability. Our approach has been to develop a
delivery strategy that can eVectively stabilize both the hydro-
philic and hydrophobic vinca alkaloids, as well as achieve
this stability at low-to-moderate drug-to-lipid ratios where
circulation lifetimes will not be compromised. We have pre-
viously discovered that a loading strategy that employs a
di- or tri-alkylammonium salt of highly sulfated, non-
polymeric polyol, sucrose octasulfate, to load and stabilize
weakly basic amphipathic drugs intraliposomally resulted in
surprising improvements in circulation lifetimes and in vivo
drug retention by the carrier [8, 11]. We hypothesize that
very high charge density in combination with the multivalent
ionic character and compactness of the molecule unachiev-
able with the previously employed polymeric polyanions
[52] makes sucrose octasulfate a better agent to immobilize a
cationic drug, such as a vinca alkaloid, inside the liposome,
while the use of exchangeable substituted ammonium cation
with the ionic radius larger than ammonium itself helps to
reduce the amount of exchangeable cation immobilized by
the non-exchangeable highly charged polyvalent anion and
therefore improves the completeness of the drug-for-cation
exchange across the liposome membrane in the course of the
drug loading. Here, we have applied this technology (which
is refered to below as “nanoliposomal formulations” or
“nanoliposomes”) to both vincristine and vinblastine
(Fig. 1a, b) to see if these vinca alkaloids could be stabilized
under a range of formulation conditions.
As described above, we were able to stabilize VCR in
liposomes, such that the half life of release was 104.5 h for
a 101.6 nm liposome loaded at 104 g VCR/mol PL (»100 g
VCR/g lipid; Fig. 3c), which is a 6.7-fold improvement
relative to the sphingosomal formulation loaded at the same
drug-to-lipid ratio [20], thus demonstrating signiWcant
retention of vincristine is possible even in the absence of
the highly cohesive lipid compositions that include sphin-
gomyelin and cholesterol. Non-pegylated liposomes typi-
cally also display pharmacokinetics that are dependent on
size, with smaller sizes being longer circulating [9,  12].
There is concern with drug-loaded liposomes is that the
high radius of membrane curvature in smaller liposomes
can sometimes cause membrane defects that give rise to
increased rates of drug leakage. However, for the smallest
VCR formulation (76.8 nm) having the lowest drug to lipid
ratio (95.1 g VCR/mol PL), the small size did not appear to
have a detrimental eVect on circulation lifetimes or in vivo
stability.
Although this manuscript focuses on VCR, a single for-
mulation of VBL was also studied to demonstrate that the
methodology was not unique to a single vinca alkaloid. The
nanoliposomal formulation of vinblastine was also markedly
more stable (T1/2 = 41.3 h at drug-to-lipid ratio of 0.14 g
VBL/g lipid) than the previously described sphingosomal
formulations at either the high or low drug-to-lipid ratio
studied (T1/2 = 3.1 h for 0.1 g VBL/g lipid and 14.7 h for the
0.3 g VBL/g lipid) [51]. Importantly, for both drugs the sta-
bility was high enough to allow liposomes suYcient time to
accumulate in solid tumors and thus to take full advantage
of the EPR phenomenon and molecular targeting of solid
tumors. Additionally, extended circulation lifetimes were
maintained over a range of formulation parameters, includ-
ing at comparatively small sizes (76.8 nm; Table 1), thus
suggesting that modiWcations that may allow for increased
extravasation and accumulation in the tumor may also be
permissible and desirable for targeted formulations.
Fig. 5 Tumor size (a–e) and body weight dynamics (f) in nude mice
with subcutaneous BT-474-M2 tumor xenografts, treated with various
vincristine formulations. All groups containing VCR were adminis-
tered at a dose of 1 mg/kg. After implantation of BT474-M2 tumor
cells animals were treated on days 20, 27, and 34 with saline control
(0 cures/9 mice) (open square), free VCR (0 cures/9mice) (Wlled
circle), Ls-VCR (1 cure/9 mice) (open diamond), and anti-HER2-ILs-
VCR (5 cures/9 mice) (Wlled diamond) (a). Error bars indicate the
standard error for each group and arrows indicate treatment times.
Both Ls-VCR formulations had a liposome size (average § standard
deviation) of 76.8 § 27.2 nm and a drug/phospholipid ratio of 95.1 g/
mol. The dynamics of body weights (b) is shown as the average %
weight change compared to the pretreatment level750 Cancer Chemother Pharmacol (2009) 64:741–751
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Immunoliposomes were prepared through conjugation of
an anti-HER2 scFv (F5) to the surface of the liposome via a
maleimide-activated PEG-DSPE anchor [33, 34]. We have
previously demonstrated that antibody fragments capable of
inducing internalization upon binding to the tyrosine kinase
receptors, EGFR and HER2/neu, were able to improve the
antitumor activity of liposomally encapsulated anticancer
drugs [29, 35, 37]. HER2-speciWc targeting of nanoliposo-
mal VCR in vitro not only restored the liposomal drug
eYciency to the level of the free drug, but also, surprisingly,
surpassed it, giving evidence that despite eVective stabiliza-
tion against drug leakage, intraliposomal sucroseoctasulfate
aVorded suYcient bioavailability of the encapsulated
VCR. Targeted antitumor eYcacy for F5-immunoliposomal
vincristine was demonstrated also in vivo in a HER2-
overexpressing breast cancer model (Fig. 5). EYcacy was
signiWcantly improved for the HER2-targeted nanoliposo-
mal vincristine when compared to nontargeted nanoliposo-
mal vincristine (p = 0.025) demonstrating the suYcient
stabilization of encapsulation can result in targeted antitu-
mor activity in solid tumors. Vincristine is used clinically in
the treatment of acute leukemia, non-Hodgkin’s malignant
lymphomas, Hodgkin’s disease, neuroblastomas, rhabdosar-
comas, and Wilm’s tumors [41]. It has also been clinically in
the treatment of melanomas [24, 25] and small cell lung can-
cer [6]. Vincristine is not used widely in the treatment of
breast cancer, although vinorelbine is used in third line treat-
ment. However, changes in the pharmacokinetics, bioavail-
ability, and tumor exposure of the drug resulting from stable
liposome encapsulation, as well as the ability to be molecu-
larly targeted may alter the range of cancers susceptible to
treatment with vincristine, which has a relatively nonspeciWc
mechanism of action. Alternatively, this proof-of-concept
study suggests that for the Wrst time vincristine may be tar-
geted for the treatment of solid tumors, and that similar for-
mulations using diVerent antibodies targeted to melanoma,
neuroblastomas, or small cell lung cancer now have the
potential for being eYcacious in treating these cancers.
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